On February 18, 2025, the Alliance for Regenerative Medicine (ARM), Cancer Patients Europe (CPE), and Fondazione Telethon co-hosted an online webinar on ‘The first Joint Clinical Assessments (JCAs) for Advanced Therapy Medicinal Products (ATMPs): What’s Next?’ The first pan-European assessments of ATMPs will mark a pivotal moment for patient access to innovative therapies.
The discussion brought together over 50 representatives from over 30 organizations – including patient organizations, medical societies and developers – for a meaningful conversation on this critical topic.
